Cargando…

Phase I evaluation of the safety, tolerability, and pharmacokinetics of GSK3640254, a next‐generation HIV‐1 maturation inhibitor

Despite advances in HIV‐1 management with antiretroviral therapy, drug resistance and toxicities with multidrug regimens can result in treatment failure. Hence, there is a continuing demand for antiretroviral agents (ARVs) with novel mechanisms of action. Maturation inhibitors inhibit HIV‐1 replicat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Joshi, Samit R., Fernando, Disala, Igwe, Stephanie, McKenzie, Litza, Krishnatry, Anu S., Halliday, Fiona, Zhan, Joyce, Greene, Thomas J., Xu, Jianfeng, Ferron‐Brady, Geraldine, Lataillade, Max, Min, Sherene
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7670640/ https://www.ncbi.nlm.nih.gov/pubmed/33200887 http://dx.doi.org/10.1002/prp2.671

Ejemplares similares

Lack of pharmacokinetic interaction between the HIV‐1 maturation inhibitor GSK3640254 and combination oral contraceptives in healthy women
por: Pene Dumitrescu, Teodora, et al.
Publicado: (2021)

Phase I evaluation of pharmacokinetics and tolerability of the HIV‐1 maturation inhibitor GSK3640254 and dolutegravir in healthy adults
por: Pene Dumitrescu, Teodora, et al.
Publicado: (2021)

A Phase I Evaluation of the Pharmacokinetics and Tolerability of the HIV-1 Maturation Inhibitor GSK3640254 and Tenofovir Alafenamide/Emtricitabine in Healthy Participants
por: Pene Dumitrescu, Teodora, et al.
Publicado: (2021)

Effects of the HIV‐1 maturation inhibitor GSK3640254 on QT interval in healthy participants
por: Zhang, Ying, et al.
Publicado: (2023)

Phase IIa Proof-of-Concept Evaluation of the Antiviral Efficacy, Safety, Tolerability, and Pharmacokinetics of the Next-Generation Maturation Inhibitor GSK3640254( )
por: Spinner, Christoph D, et al.
Publicado: (2022)

Relative Bioavailability and Food Effect of GSK3640254 Tablet and Capsule Formulations in Healthy Participants
por: Johnson, Mark, et al.
Publicado: (2022)

GSK3640254 Is a Novel HIV-1 Maturation Inhibitor with an Optimized Virology Profile
por: Dicker, Ira, et al.
Publicado: (2022)

Population pharmacokinetic modeling of molibresib and its active metabolites in patients with solid tumors: A semimechanistic autoinduction model
por: Krishnatry, Anu Shilpa, et al.
Publicado: (2021)

An Adaptive Physiologically Based Pharmacokinetic–Driven Design to Investigate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics of Molibresib (GSK525762) in Healthy Female Volunteers
por: Riddell, Kylie, et al.
Publicado: (2020)

Resistance profile of the HIV-1 maturation inhibitor GSK3532795 in vitro and in a clinical study
por: Dicker, Ira, et al.
Publicado: (2019)

Integrating In Vitro Biopharmaceutics into Physiologically Based Biopharmaceutic Model (PBBM) to Predict Food Effect of BCS IV Zwitterionic Drug (GSK3640254)
por: Stamatopoulos, Konstantinos, et al.
Publicado: (2023)

Exposure–response analysis of adverse events associated with molibresib and its active metabolites in patients with solid tumors
por: Krishnatry, Anu Shilpa, et al.
Publicado: (2021)

Safety, efficacy, and dose response of the maturation inhibitor GSK3532795 (formerly known as BMS-955176) plus tenofovir/emtricitabine once daily in treatment-naive HIV-1-infected adults: Week 24 primary analysis from a randomized Phase IIb trial
por: Morales-Ramirez, Javier, et al.
Publicado: (2018)

A phase I, first‐in‐human study investigating the safety, tolerability, and pharmacokinetics of the maturation inhibitor GSK3739937
por: Benn, Paul D., et al.
Publicado: (2023)

Development of a Prototype, Once-Daily, Modified-Release Formulation for the Short Half-Life RIPK1 Inhibitor GSK2982772
por: Tompson, Debra J., et al.
Publicado: (2021)

Development of a Once-Daily Modified-Release Formulation for the Short Half-Life RIPK1 Inhibitor GSK2982772 using DiffCORE Technology
por: Tompson, Debra, et al.
Publicado: (2022)

The safety, tolerability, and pharmacokinetic profile of GSK2838232, a novel 2nd generation HIV maturation inhibitor, as assessed in healthy subjects
por: Johnson, Mark, et al.
Publicado: (2018)

The Second-Generation Maturation Inhibitor GSK3532795 Maintains Potent Activity Toward HIV Protease Inhibitor–Resistant Clinical Isolates
por: Ray, Neelanjana, et al.
Publicado: (2017)

Population pharmacokinetics of belantamab mafodotin, a BCMA‐targeting agent in patients with relapsed/refractory multiple myeloma
por: Rathi, Chetan, et al.
Publicado: (2021)

Population pharmacokinetics of cabazitaxel in patients with advanced solid tumors
por: Ferron, Géraldine M., et al.
Publicado: (2013)

A randomized study of the safety and pharmacokinetics of GSK3358699, a mononuclear myeloid‐targeted bromodomain and extra‐terminal domain inhibitor
por: Brown, Jack A., et al.
Publicado: (2021)

731. Pharmacokinetics of Gepotidacin (GSK2140944) in Subjects with Hepatic Impairment
por: Hands, Jonathan T, et al.
Publicado: (2019)

Intrinsic resistance of HIV-2 and SIV to the maturation inhibitor GSK2838232
por: Smith, Robert A., et al.
Publicado: (2023)

The Effect of Food and Formulation on the Pharmacokinetics, Safety, and Tolerability of GSK1322322 in Healthy Volunteers
por: Naderer, Odin, et al.
Publicado: (2015)

1115. Evaluation of Gepotidacin (GSK2140944) Pharmacokinetics and Food Effect in Japanese Subjects
por: Hossain, Mohammad, et al.
Publicado: (2021)

Pharmacokinetic, Safety, and Tolerability Evaluations of Gepotidacin (GSK2140944) in Healthy Japanese Participants
por: Barth, Aline, et al.
Publicado: (2022)

Evaluation of the safety, pharmacokinetics, pharmacodynamics, and drug-drug interaction potential of a selective Lp-PLA2 inhibitor (GSK2647544) in healthy volunteers
por: Wu, Kai, et al.
Publicado: (2016)

Comparison of the Pharmacokinetics of RIPK1 Inhibitor GSK2982772 in Healthy Western and Japanese Subjects
por: Tompson, Debra J., et al.
Publicado: (2020)

Localised learning: mobilising belonging among mature-aged students in low socio-economic status regional and remote areas
por: Crawford, Nicole, et al.
Publicado: (2022)

Safety, tolerability, and pharmacokinetics of a single ascending subcutaneous dose of GSK3772847 in healthy participants
por: Pefani, Eleni, et al.
Publicado: (2023)

Correction: Resistance profile of the HIV-1 maturation inhibitor GSK3532795 in vitro and in a clinical study
Publicado: (2019)

The effects of alcohol on the pharmacokinetics and pharmacodynamics of the selective mu-opioid receptor antagonist GSK1521498 in healthy subjects
por: Ziauddeen, Hisham, et al.
Publicado: (2013)

The pharmacokinetics and pharmacodynamics of danirixin (GSK1325756) − a selective CXCR2 antagonist − in healthy adult subjects
por: Miller, Bruce E., et al.
Publicado: (2015)

Randomized clinical study of safety, pharmacokinetics, and pharmacodynamics of RIPK1 inhibitor GSK2982772 in healthy volunteers
por: Weisel, Kathleen, et al.
Publicado: (2017)

Antiviral Activity, Safety, and Exposure–Response Relationships of GSK3532795, a Second-Generation Human Immunodeficiency Virus Type 1 Maturation Inhibitor, Administered as Monotherapy or in Combination With Atazanavir With or Without Ritonavir in a Phase 2a Randomized, Dose-Ranging, Controlled Trial (AI468002)
por: Hwang, Carey, et al.
Publicado: (2017)

Proteolytic maturation of α(2)δ controls the probability of synaptic vesicular release
por: Ferron, Laurent, et al.
Publicado: (2018)

Safety, Tolerability and Pharmacokinetics of Single Doses of Oxytocin Administered via an Inhaled Route in Healthy Females: Randomized, Single-blind, Phase 1 Study()
por: Fernando, Disala, et al.
Publicado: (2017)

Pharmacokinetic Modeling of [(11)C]GSK-189254, PET Tracer Targeting H(3) Receptors, in Rat Brain
por: Ghazanfari, Nafiseh, et al.
Publicado: (2022)

Unusually High Affinity of the PLK Inhibitors RO3280 and GSK461364 to HSA and Its Possible Pharmacokinetic Implications
por: Fernández-Sainz, Jesús, et al.
Publicado: (2023)

Viral Drug Resistance Through 48 Weeks, in a Phase 2b, Randomized, Controlled Trial of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir
por: Lataillade, Max, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_veaaikpobg0j1act47dor99f6c